- Home
- RVPH vs IKNA Comparison
RVPH vs IKNA Comparison
Compare RVPH & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- IKNA
- Stock Information
- Founded
- RVPH 2006
- IKNA 2016
- Country
- RVPH United States
- IKNA United States
- Employees
- RVPH N/A
- IKNA N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- RVPH Health Care
- IKNA Health Care
- Exchange
- RVPH Nasdaq
- IKNA Nasdaq
- Market Cap
- RVPH 32.8M
- IKNA 63.7M
- IPO Year
- RVPH N/A
- IKNA 2021
- Fundamental
- Price
- RVPH $0.43
- IKNA $1.37
- Analyst Decision
- RVPH Strong Buy
- IKNA Strong Buy
- Analyst Count
- RVPH 5
- IKNA 1
- Target Price
- RVPH $9.00
- IKNA $4.00
- AVG Volume (30 Days)
- RVPH 3.5M
- IKNA 63.1K
- Earning Date
- RVPH 08-13-2025
- IKNA 08-07-2025
- Dividend Yield
- RVPH N/A
- IKNA N/A
- EPS Growth
- RVPH N/A
- IKNA N/A
- EPS
- RVPH N/A
- IKNA N/A
- Revenue
- RVPH N/A
- IKNA N/A
- Revenue This Year
- RVPH N/A
- IKNA N/A
- Revenue Next Year
- RVPH N/A
- IKNA N/A
- P/E Ratio
- RVPH N/A
- IKNA N/A
- Revenue Growth
- RVPH N/A
- IKNA N/A
- 52 Week Low
- RVPH $0.30
- IKNA $0.97
- 52 Week High
- RVPH $4.28
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- RVPH 37.84
- IKNA 55.10
- Support Level
- RVPH $0.38
- IKNA $1.31
- Resistance Level
- RVPH $0.45
- IKNA $1.42
- Average True Range (ATR)
- RVPH 0.06
- IKNA 0.05
- MACD
- RVPH 0.00
- IKNA -0.00
- Stochastic Oscillator
- RVPH 24.40
- IKNA 51.24
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.